Spectranetics out of Colorado Springs, Colorado won the CE Mark in Europe to bring to market its AngioSculptX Drug-coated PTCA (percutaneous transluminal coronary angioplasty) Scoring Balloon Catheter. Originally developed by AngioScore, a company purchased by Spectranetics, the device is a drug coated version of the company’s proven AngioSculpt PTCA scoring balloon catheter and is indicated for treatment of coronary artery stenosis, which includes in-stent restenosis.
“AngiosculptX represents a unique coronary scoring technology that incorporates a drug coating. Given its clinical results, it is a significant advancement in therapy options for patients,” said Professor Bruno Scheller of Saarlandes University Clinic in Homburg, Germany, in a statement.
Via: Spectranetics…